ASSOCIATION SNPS IN OSTEONECROSIS PATIENTS WITH SLE IN TAIWAN AND THEIR POTENTIAL USE FOR EARLY DETECTION

W. T. Huang; C. J. Chen; H. J. Chang; F. Y. Chung; S. R. Lin; Y. F. Chen; G. J. Wang

doi:10.1302/1358-992X.94BSUPP_VIII.ARCO2009-037

Article alerts Social media

Current issue

Research

ASSOCIATION SNPS IN OSTEONECROSIS PATIENTS WITH SLE IN TAIWAN AND THEIR POTENTIAL USE FOR EARLY DETECTION

Yokohama, Japan, November 2009 meeting

W. T. Huang
C. J. Chen
H. J. Chang
F. Y. Chung
S. R. Lin
Y. F. Chen
G. J. Wang

ASSOCIATION SNPS IN OSTEONECROSIS PATIENTS WITH SLE IN TAIWAN AND THEIR POTENTIAL USE FOR EARLY DETECTION

Huang WT, Chen CJ, Chang HJ, et al. ASSOCIATION SNPS IN OSTEONECROSIS PATIENTS WITH SLE IN TAIWAN AND THEIR POTENTIAL USE FOR EARLY DETECTION. Orthop Procs. 2012;94-B(SUPP_VIII):37-37. doi:10.1302/1358-992X.94BSUPP_VIII.ARCO2009-037

Huang, W. T., et al. “ASSOCIATION SNPS IN OSTEONECROSIS PATIENTS WITH SLE IN TAIWAN AND THEIR POTENTIAL USE FOR EARLY DETECTION.” Orthopaedic Proceedings, vol. 94-B, no. SUPP_VIII, 2012, pp. 37-37., https://doi.org/10.1302/1358-992X.94BSUPP_VIII.ARCO2009-037

Huang, W. T., Chen, C. J., Chang, H. J., Chung, F. Y., Lin, S. R., Chen, Y. F., & Wang, G. J. (2012). ASSOCIATION SNPS IN OSTEONECROSIS PATIENTS WITH SLE IN TAIWAN AND THEIR POTENTIAL USE FOR EARLY DETECTION. Orthopaedic Proceedings, 94-B(SUPP_VIII), 37-37. https://doi.org/10.1302/1358-992X.94BSUPP_VIII.ARCO2009-037

Huang, W. T., Chen, C. J., Chang, H. J., Chung, F. Y., Lin, S. R., Chen, Y. F. et al. (2012) “ASSOCIATION SNPS IN OSTEONECROSIS PATIENTS WITH SLE IN TAIWAN AND THEIR POTENTIAL USE FOR EARLY DETECTION.” Orthopaedic Proceedings, 94-B(SUPP_VIII), pp. 37-37. Available at: https://doi.org/10.1302/1358-992X.94BSUPP_VIII.ARCO2009-037

Huang, W. T., C. J. Chen, H. J. Chang, F. Y. Chung, S. R. Lin, Y. F. Chen, and G. J. Wang. “ASSOCIATION SNPS IN OSTEONECROSIS PATIENTS WITH SLE IN TAIWAN AND THEIR POTENTIAL USE FOR EARLY DETECTION.” Orthopaedic Proceedings 94-B, no. SUPP_VIII (2012): 37-37. https://doi.org/10.1302/1358-992X.94BSUPP_VIII.ARCO2009-037

Huang WT, Chen CJ, Chang HJ, Chung FY, Lin SR, Chen YF, et al. ASSOCIATION SNPS IN OSTEONECROSIS PATIENTS WITH SLE IN TAIWAN AND THEIR POTENTIAL USE FOR EARLY DETECTION. Orthop Procs. 2012 Mar 1;94-B(SUPP_VIII):37-37. https://doi.org/10.1302/1358-992X.94BSUPP_VIII.ARCO2009-037

Copy to clipboard

BibTeX

EndNote

RIS

Abstract

Introduction

Osteonecrosis (ON) is a disease that ultimately results in bone collapse. We investigated the correlation between SNPs and osteonecrosis.

Methods

In this study, 109 patients with systematic lupus erythematosus (SLE) (21 with and 88 without osteonecrosis) were collected for genotype analysis of 7 genes including VEGF, MTHFR, eNOS, and PAI-1 related to the blood system and BMP2 and PPARγ-2, genes that regulate the differentiation of bone marrow stromal cells.

Results

The result of the combined analysis of the susceptible BMP2 (rs3178250) TC genotype, MTHFR (rs1801133) CC genotype and VEGF (rs833069) AA genotype was OR: 0.185, 95 % CI:0.044 - 0.774 (p=0.021). In addition, when the different genotype combinations were analyzed the result for BMP2 (rs3178250) TC, MTHFR (rs1801133)CC, and PPARγ-2 (rs11128596) AA genotype was OR:0.096, 95 % CI:0.044-0.774 (p=0.012); the result for BMP2(rs3178250) TT, VEGF (rs833069) AG, and PPARγ-2 (rs11128596) CA genotype was OR:0.099, 95 % CI:0.016-0.597 (p=0.012); and that of VEGF AA, eNOS 298T GT, and eNOS 27bp tandem repeat 5R5R genotype was OR:0.060, 95 % CI:0.006- 0.588 (p =0.016), respectively.

Conclusion

The results of this research provides an important reference to predict corticosteroid-associated osteonecrosis for SLE patients, providing related genotypic molecular epidemiology and possible discussion on mechanisms of pathogenicity for corticosteroid-associated osteonecrosis in SLE patients in Taiwan. The result of this research not only serves as a reference for possible ON risk factors in SLE patients with chronic corticosteroid use, but also forms a basis for treatment and medication in the clinical setting.